Search Results - "Seaman, John J."

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group by ROSEN, Lee S, GORDON, David, REITSMA, Dirk, SEAMAN, John J, TCHEKMEDYIAN, Simon, YANAGIHARA, Ronald, HIRSH, Vera, KRZAKOWSKI, M, PAWLICKI, M, DE SOUZA, Paul, MING ZHENG, URBANOWITZ, Gladys

“…To assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to solid tumors other than breast or prostate cancer. Patients…”
Get full text

Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer by SMALL, Eric J, SMITH, Matthew R, SEAMAN, John J, PETRONE, Stephanie, KOWALSKI, Mildred Ortu

“…Bone metastases occur in approximately 80% of patients with advanced prostate cancer. Pain is common in these patients. The purpose of this study was to…”
Get full text

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial by ROSEN, Lee S, GORDON, David, CHEN, Bee-Lian, SEAMAN, John J, KAMINSKI, Mary, HOWELL, Anthony, BELCH, Andrew, MACKEY, John, APFFELSTAEDT, Justus, HUSSEIN, Mohamad A, COLEMAN, Robert E, REITSMA, Dirk J

“…The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions…”
Get full text

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study by BERENSON, James R, ROSEN, Lee S, HOWELL, Anthony, PORTER, Lester, COLEMAN, Robert E, MORLEY, Walter, DREICER, Robert, KUROSS, Steven A, LIPTON, Allan, SEAMAN, John J

“…This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients…”
Get full text

Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial by THERIAULT, R. L, LIPTON, A, KNIGHT, R. D, MELLARS, K, HEFFERNAN, M, REITSMA, D. J, HORTOBAGYI, G. N, LEFF, R, GLÜCK, S, STEWART, J. F, COSTELLO, S, KENNEDY, I, SIMEONE, J, SEAMAN, J. J

“…PURPOSE: To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with…”
Get full text

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases long term follow-up of two randomized, placebo-controlled trials by LIPTON, A, THERIAULT, R. L, HORTOBAGYI, G. N, SIMEONE, J, KNIGHT, R. D, MELLARS, K, REITSMA, D. J, HEFFERNAN, M, SEAMAN, J. J

“…Pamidronate therapy previously has been shown to reduce skeletal complications effectively for up to 12 months in breast carcinoma patients with bone…”
Get full text

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial by Rosen, L S, Gordon, D, Kaminski, M, Howell, A, Belch, A, Mackey, J, Apffelstaedt, J, Hussein, M, Coleman, R E, Reitsma, D J, Seaman, J J, Chen, B L, Ambros, Y

“…Zoledronic acid, a new and more potent bisphosphonate, was compared with pamidronate, the current standard treatment for patients with osteolytic or mixed bone…”
Get more information

The effect of single intravenous doses of cimetidine or ranitidine on gastric secretion by Frank, W O, Peace, K E, Watson, M, Seaman, J J, Szego, P L, Braverman, A, Mico, B, Dickson, B

“…Intravenous cimetidine, 300 mg or 400 mg, or ranitidine, 50 mg, was administered as a single dose to 36 volunteers in a randomized, crossover fashion…”
Get more information

Ranitidine and Cimetidine by Humphries, Thomas J, Frank, William O, Seaman, John J, Myerson, Ralph M

“…To the Editor.—It is to be expected that a review of the recently approved H2-receptor antagonist, ranitidine, include reference to cimetidine, the pioneer…”
Get full text

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study by Glover, D, Lipton, A, Keller, A, Miller, A A, Browning, S, Fram, R J, George, S, Zelenakas, K, Macerata, R S, Seaman, J J

“…Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a…”
Get more information

Pharmacokinetics of Pamidronate Disodium in Patients with Cancer with Normal or Impaired Renal Function by Berenson, James R., Rosen, Lee, Vescio, Robert, Lau, Henry S., Woo, Margie, Sioufi, Antoine, Kowalski, M. Ortu, Knight, Robert D., Seaman, John J.

“…Pamidronate is a second‐generation bisphosphonate that undergoes negligible biodegradation and is eliminated exclusively by renal excretions. Nineteen cancer…”
Get full text

The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases by Coleman, R E, Seaman, J J

“…Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical…”
Get more information

Theophylline interaction with H2 receptor antagonists by Myerson, R M, Seaman, J J, Frank, W O

Get more information

Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma by Rosen, Lee S., Gordon, David, Kaminski, Mary, Howell, Anthony, Belch, Andrew, Mackey, John, Apffelstaedt, Justus, Hussein, Mohamad A., Coleman, Robert E., Reitsma, Dirk J., Chen, Bee‐Lian, Seaman, John J.

“…BACKGROUND The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone…”
Get full text

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases by Lipton, Allan, Theriault, Richard L., Hortobagyi, Gabriel N., Simeone, Joseph, Knight, Robert D., Mellars, Kathleen, Reitsma, Dirk J., Heffernan, Maika, Seaman, John J.

“…BACKGROUND Pamidronate therapy previously has been shown to reduce skeletal complications effectively for up to 12 months in breast carcinoma patients with…”
Get full text

Zoledronic acid reduces skeletal‐related events in patients with osteolytic metastases by Berenson, James R., Rosen, Lee S., Howell, Anthony, Porter, Lester, Coleman, Robert E., Morley, Walter, Dreicer, Robert, Kuross, Steven A., Lipton, Allan, Seaman, John J.

“…BACKGROUND This study evaluated the dose–response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5‐minute infusion in…”
Get full text

Exploring psychiatric prescribing practices: the relationship between the role of the provider and the appropriateness of prescribing by Seaman, J J, Cornfield, R M, Cummings, D M, Peterson, C W, Lyon, J

“…The prescribing habits of psychiatrists and neurologists in a large, urban Veterans Administration medical center were surveyed. It was determined that these…”
Get more information

Ranitidine

Get more information

A note on tests for interaction in quantal response data by HOLT, Melinda A, STAMEY, James D, SEAMAN, John W, YOUNG, Dean M

Get full text

Financial impact of a pharmacist-managed medication refill clinic by Nelson, L A, Downs, G E, Cummings, D M, Seaman, J J

Get more information